cas 179554-98-4|| where to buy 4-((Methylthio)methyl)pyridin-2-amine

Produktname:4-((Methylthio)methyl)pyridin-2-amine

IUPAC Name:4-[(methylsulfanyl)methyl]pyridin-2-amine

Packungseinheit	Verfügbarer Vorrat	Preis($)
CM318292-250mg	in stock	ȅǑŪ
CM318292-1g	1-2 Weeks	ǫŪŪ
CM318292-5g	1-2 Weeks	ȅȅǑƴ

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

Chemische Bezeichnung

CAS-Nummer

Menge*

Erforderliche Spezifikationen*
(Gehalt %, Materialqualität etc.)

Name des Ansprechpartners*

E-Mail des Ansprechpartners*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 179554-98-4 regularly via the above email.

Zusätzliche Hinweise

Verification code*

refresh

: CAS-Nr.:179554-98-4; Molekulare Formel:C7H10N2S; Schmelzpunkt:-; SMILES-Code:NC1=NC=CC(CSC)=C1; Dichte:

: Katalognummer:CM318292; Molekulargewicht:154.23; Siedepunkt:; Mdl-Nr.:MFCD16765791; Lagerung:Keep in dark place, inert atmosphere, store at room temperature.

: Pyridines; Pyridine is a six-membered heterocyclic compound containing one nitrogen heteroatom. Pyridine and piperidine are the most frequently occurring heterocyclic building blocks in drug molecules. According to incomplete statistics, there are currently more than 180 drugs containing pyridine or piperidine structure that have been marketed, nearly 1/5 of the drugs approved for marketing in recent years contain these two structures.; Pyridine | C5H5N | Pyridine Supplier/Distributor/Manufacturer - Chemenu; Pyridine,Pyridine Wholesale,Pyridine for Sale,Pyridine Supplier,Pyridine Distributor,Pyridine Manufacturer; Pyridine is a basic heterocyclic organic compound with the chemical formula C5H5N. It is structurally related to benzene, with one methine group (=CH−) replaced by a nitrogen atom. It is a highly flammable, weakly alkaline, water-miscible liquid with a distinctive, unpleasant fish-like smell.

: Enitociclib; On January 7, 2024, Vincerx announced promising clinical results from a Phase 1 NIH-sponsored study of enitociclib in combination with venetoclax and prednisone for the treatment of relapsed/refractory lymphoma. Enitociclib is a highly selective CDK9 inhibitor that prevents activation of RNA polymerase II, resulting in reduction of known oncogenes MYC and MCL1.